報價延遲最少15分鐘:2025/01/12 03:25 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
36.02 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
1.55/2.42
|
|
企業價值
10.04B
|
| 資產負債 |
|
每股賬面淨值
7.97
|
| 現金流量 |
|
現金流量率
0.05
|
| 損益表 |
|
收益
1.83B
|
|
每股收益
6.21
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/12 03:25 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. |